Skip to content
PubMed This is a summary of 16 peer-reviewed journal articles Updated
Pulmonology

The Biology and Diagnosis of MAC

At a Glance

Pulmonary MAC is diagnosed by combining compatible symptoms, characteristic chest imaging, and laboratory evidence—usually two positive sputum cultures collected on different days, one positive bronchoscopy sample, or biopsy findings with a positive culture.

Confirming a diagnosis of Mycobacterium avium complex (MAC) is more complex than a standard bacterial infection like strep throat. Because these bacteria live naturally in our environment, finding them in a single cough sample does not automatically mean you are sick [1]. Doctors follow a strict set of international guidelines (the 2020 ATS/ERS/ESCMID/IDSA criteria) to ensure that the bacteria are actually causing disease rather than just “passing through” [2][3].

The Biology of MAC: Why It Is Hard to Kill

MAC belongs to a group called non-tuberculous mycobacteria (NTM). While it is related to the bacteria that cause tuberculosis (TB), MAC has unique biological defenses that make it particularly stubborn [2][3]:

  • Lipid-Rich Membrane: MAC has a thick outer shell made of long-chain fatty acids (lipids) [4]. This makes the bacteria waterproof (hydrophobic) and naturally resistant to common disinfectants and many standard antibiotics [4][5]. You do not need aggressive chemical cleaning at home, but this explains why it persists in your lungs.
  • Biofilm Formation: These bacteria are experts at building biofilms—communities that stick to surfaces like plumbing pipes or the lining of your lungs [4]. Inside a biofilm, the bacteria are shielded from your immune system and from the full force of antibiotic treatments [4][6].
  • Slow Growth: Unlike common bacteria that multiply in minutes, MAC grows very slowly [4]. This slow pace is why it can take weeks for a lab to “grow out” a culture and why treatment courses last for over a year [4][7].

The Three Pillars of a Pulmonary MAC Diagnosis

To be formally diagnosed with pulmonary (lung) MAC, you must meet all three of the following criteria [2][3]:

  1. Clinical Symptoms: You must have symptoms that match the disease, such as a persistent cough, fatigue, or night sweats, and your doctor must rule out other possible causes for these symptoms [2][3].
  2. Radiographic (Imaging) Evidence: A chest X-ray or, more commonly, a High-Resolution CT (HRCT) scan must show specific damage, such as small nodules, “tree-in-bud” patterns (which look like budding branches), or cavities (holes in the lung tissue) [2][3][8].
  3. Microbiologic Evidence: This is the most technical part of the diagnosis. You must have:
    • Two or more positive sputum (mucus) cultures collected on different days [3][1].
    • OR at least one positive culture from a Bronchoalveolar Lavage (BAL), which is a procedure where a doctor uses a scope to rinse a small part of the lung and collect the fluid [3][8].
    • OR a lung biopsy showing the bacteria under a microscope alongside a positive culture [3][1].

Why isn’t one sputum sample enough? Because MAC is in the water we drink and the air we breathe, it is possible to have a culture where the bacteria were simply in your mouth or throat at the time of the test (colonization) [1][9]. Requiring two separate positive samples shows persistent recovery of viable organisms [3].

Disseminated MAC: When the Infection Spreads

In people with severely weakened immune systems (such as those with advanced HIV, solid organ transplants, or specific genetic conditions), MAC can become disseminated [10][11]. This means the bacteria have entered the bloodstream and moved to other parts of the body. Diagnosis for this form is different; it does not rely on sputum criteria. It requires finding the bacteria in a “sterile” site where it should never be, such as your blood, bone marrow, or a lymph node [10][12].

Deciphering Your Lab Report

When you look at your laboratory results, you will see several key terms that describe how the bacteria were found and what kills them:

  • AFB Smear (Acid-Fast Bacilli): This is a quick test where the lab puts your sample under a microscope with a special red stain. A “positive” smear indicates there are acid-fast organisms present, which often indicates a higher organism burden [8][13]. However, an AFB smear cannot tell the difference between MAC and tuberculosis (TB) [8]. A negative smear does not mean you are clear; it just means there weren’t enough bacteria to see easily.
  • Culture: This is the “gold standard” test where the lab tries to grow the bacteria in a dish. This is necessary to confirm exactly which species of NTM you have [3][14].
  • Macrolide Susceptibility: This is the most important part of the report for your treatment. It tests whether your specific strain of MAC can be killed by macrolides (the class of antibiotics including Azithromycin and Clarithromycin) [15]. If your strain is resistant to these drugs, the standard treatment will not work, and your doctor must use a much more complex regimen [15][16]. Current guidelines mandate that this test be performed for every new diagnosis [15].

Common questions in this guide

How is pulmonary MAC diagnosed?
Pulmonary MAC is diagnosed when three parts line up: compatible symptoms, characteristic chest imaging, and laboratory evidence of MAC. Laboratory evidence usually means at least two positive sputum cultures collected on different days, one positive sample from a bronchoscopy wash, or a lung biopsy with a positive culture. Clinicians also consider other possible causes of the symptoms.
Why do I need two positive sputum cultures for MAC?
MAC is common in water and soil, so a single positive sputum result may reflect temporary contamination or colonization in the mouth or throat rather than lung disease. Two positive cultures from samples collected on different days provide stronger evidence that live MAC is persistently present. Diagnosis still requires compatible symptoms and imaging.
What does a positive or negative AFB smear mean?
An AFB smear uses a special stain to look for acid-fast organisms under a microscope. A positive result often suggests a higher number of organisms, but it cannot tell MAC from tuberculosis; a negative smear does not rule out MAC because fewer bacteria may be present. Culture is needed to identify the specific type of non-tuberculous mycobacteria.
What does macrolide susceptibility mean on a MAC test report?
Macrolide susceptibility testing checks whether the MAC strain is likely to respond to azithromycin or clarithromycin. If the strain is resistant, the usual treatment may not work and the clinician may need a more complex treatment plan. Guidelines recommend this testing for each new MAC diagnosis.
What can a CT scan show in MAC lung disease?
CT findings that can support pulmonary MAC include small lung nodules, tree-in-bud patterns, and cavities, which are hollow areas in lung tissue. A clinician may describe the overall pattern as nodular bronchiectatic or cavitary. Imaging alone does not confirm MAC; symptoms and laboratory testing are also needed.
How is disseminated MAC diagnosed?
Disseminated MAC occurs when bacteria spread through the bloodstream to sites beyond the lungs, especially in people with severely weakened immune systems. It is diagnosed by finding MAC in a normally sterile site, such as blood, bone marrow, or a lymph node, rather than by the pulmonary sputum criteria.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Based on the 2020 guidelines, do I meet all three criteria (symptoms, imaging, and microbiology) for a MAC diagnosis?
  2. 2.Why do I need a second positive sputum culture before we can confirm this is MAC lung disease?
  3. 3.Has my lab report confirmed 'macrolide susceptibility' for this specific strain of MAC?
  4. 4.Does my CT scan show 'nodular bronchiectatic' or 'cavitary' patterns, and how does that change my diagnosis?
  5. 5.If my AFB smear was negative but my culture was positive, what does that tell us about the amount of bacteria in my lungs?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (16)
  1. 1

    Limited value of transbronchial lung biopsy for diagnosing Mycobacterium avium complex lung disease.

    Sekine A, Saito T, Satoh H, et al.

    The clinical respiratory journal 2017; (11(6)):1018-1023 doi:10.1111/crj.12459.

    PMID: 26808915
  2. 2

    Treatment of nontuberculous mycobacterial pulmonary disease: an official ATS/ERS/ESCMID/IDSA clinical practice guideline.

    Daley CL, Iaccarino JM, Lange C, et al.

    The European respiratory journal 2020; (56(1)) doi:10.1183/13993003.00535-2020.

    PMID: 32636299
  3. 3

    Mycobacterium avium Complex: Addressing Gaps in Diagnosis and Management.

    Daley CL, Winthrop KL

    The Journal of infectious diseases 2020; (222(Suppl 4)):S199-S211 doi:10.1093/infdis/jiaa354.

    PMID: 32814943
  4. 4

    Mycobacterium avium complex: Adherence as a way of life.

    Falkinham JO

    AIMS microbiology 2018; (4(3)):428-438 doi:10.3934/microbiol.2018.3.428.

    PMID: 31294225
  5. 5

    Detection of Mycobacterial DNA in Human Bone Marrow.

    González-Escalada A, Rebollo MJ, Barrios Payan J, et al.

    Microorganisms 2023; (11(7)) doi:10.3390/microorganisms11071788.

    PMID: 37512960
  6. 6

    Treatment Dilemmas in Disseminated Nontuberculous Mycobacterial Infections With Interferon-gamma Autoantibodies.

    King EM, Weaver VK, Kestler MH

    Open forum infectious diseases 2021; (8(7)):ofab253 doi:10.1093/ofid/ofab253.

    PMID: 34250191
  7. 7

    [Nontuberculous mycobacterial pulmonary disease - The new ATS/ERS/ESCMID/IDSA Guideline].

    Wagner D, Lange C

    Deutsche medizinische Wochenschrift (1946) 2020; (145(16)):1145-1151 doi:10.1055/s-0043-124159.

    PMID: 32791550
  8. 8

    The characteristics of patients with pulmonary Mycobacterium avium-intracellulare complex disease diagnosed by bronchial lavage culture compared to those diagnosed by sputum culture.

    Maekawa K, Naka M, Shuto S, et al.

    Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy 2017; (23(9)):604-608 doi:10.1016/j.jiac.2017.05.008.

    PMID: 28606745
  9. 9

    Update on pulmonary disease due to non-tuberculous mycobacteria.

    Stout JE, Koh WJ, Yew WW

    International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases 2016; (45()):123-34.

    PMID: 26976549
  10. 10

    Disseminated Mycobacterium avium Complex Infection in an HIV Patient with a History of Talaromyces marneffei: Diagnostic Value of Blind Subculture and Suspected Management Challenges of Immune Reconstitution Inflammatory Syndrome.

    Niu X, Yu Q, Gu J, et al.

    Infection and drug resistance 2026; (19()):606947 doi:10.2147/IDR.S606947.

    PMID: 42370219
  11. 11

    Disseminated Mycobacterium avium complex infection in a woman with anti-interferon-γ autoantibodies.

    Dahl VN, Nielsen BU, Wejse CM, et al.

    IDCases 2021; (26()):e01300 doi:10.1016/j.idcr.2021.e01300.

    PMID: 34692415
  12. 12

    Disseminated Mycobacterium avium complex infection as a differential diagnosis of tuberculosis in HIV patients.

    Chiang CH, Lee GH, Chiang TH, et al.

    The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease 2020; (24(9)):922-927 doi:10.5588/ijtld.19.0602.

    PMID: 33156759
  13. 13

    Natural history of Mycobacterium avium complex lung disease in untreated patients with stable course.

    Hwang JA, Kim S, Jo KW, Shim TS

    The European respiratory journal 2017; (49(3)) doi:10.1183/13993003.00537-2016.

    PMID: 28275170
  14. 14

    Comparison of Clinical Features, Virulence, and Relapse among Mycobacterium avium Complex Species.

    Boyle DP, Zembower TR, Reddy S, Qi C

    American journal of respiratory and critical care medicine 2015; (191(11)):1310-7 doi:10.1164/rccm.201501-0067OC.

    PMID: 25835090
  15. 15

    Sitafloxacin-Containing Regimen for the Treatment of Refractory Mycobacterium avium Complex Lung Disease.

    Asakura T, Suzuki S, Fukano H, et al.

    Open forum infectious diseases 2019; (6(4)):ofz108 doi:10.1093/ofid/ofz108.

    PMID: 31111076
  16. 16

    Clinical characteristics and treatment outcomes of patients with macrolide-resistant Mycobacterium avium complex pulmonary disease: a systematic review and meta-analysis.

    Park Y, Lee EH, Jung I, et al.

    Respiratory research 2019; (20(1)):286 doi:10.1186/s12931-019-1258-9.

    PMID: 31852452

This page explains MAC biology and diagnosis for informational purposes only and does not constitute medical advice. Your pulmonologist or infectious disease clinician should interpret your symptoms, imaging, and test results.

Get notified when new evidence is published on Mycobacterium avium complex disease.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.